Document is current
Any future updates will be listed below
-
Authors
Mekinian, Arsene https://orcid.org/0000-0003-2849-3049
Zhao, Lin Pierre https://orcid.org/0000-0001-5035-4470
Chevret, Sylvie
Desseaux, Kristell
Pascal, Laurent
Comont, Thibaut
Maria, Alexandre
Peterlin, Pierre
Terriou, Louis
D’Aveni Piney, Maud
Gourin, Marie-Pierre https://orcid.org/0000-0002-0143-5327
Vey, Norbert https://orcid.org/0000-0001-7027-040X
Rauzy, Odile Beyne
Grobost, Vincent
Bezanahary, Holy
Dimicoli-Salazar, Sophie
Banos, Anne
Wickenhauser, Stefan
De Renzis, Benoit
Durot, Eric https://orcid.org/0000-0003-3463-0089
Natarajan-Amé, Shanti
Voillat, Laurent
Chermat, Fatiha
Lemaire, Karine
Jachiet, Vincent
Himberlin, Chantal
Thépot, Sylvain
Diaz, Jose Miguel Torregrosa
Frenzel, Laurent
Gyan, Emmanuel https://orcid.org/0000-0002-7651-9189
Denis, Guillaume https://orcid.org/0000-0003-0434-265X
Hirsch, Pierre
Kosmider, Olivier https://orcid.org/0000-0002-6021-4057
Ades, Lionel https://orcid.org/0000-0002-9020-8766
Fain, Olivier
Fenaux, Pierre
- License Information
-
More Information
Article History
Received: 28 June 2022
Revised: 22 August 2022
Accepted: 2 September 2022
First Online: 14 September 2022
Competing interests
: A Mekinian is an investigator of Celgene, Roche, Chugai founded trials with APHP and Hôpital 15–20 promotion; and received several fees for advisory boards from LFB, Sanofi, Shire, and Celgene. The other authors declare no competing interests.
